Targeting BCL2-Proteins for the Treatment of Solid Tumours
about
Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypesMiR-34a and miR-206 act as novel prognostic and therapy biomarkers in cervical cancer.Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factorsSmall Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.Lovastatin exerts protective effects on endothelial cells via upregulation of PTK2B.PNT2258, a novel deoxyribonucleic acid inhibitor, induces cell cycle arrest and apoptosis via a distinct mechanism of action: a new class of drug for non-Hodgkin's lymphoma.How to unleash mitochondrial apoptotic blockades to kill cancers?Novel quinolone chalcones targeting colchicine-binding pocket kill multidrug-resistant cancer cells by inhibiting tubulin activity and MRP1 function.Systemic Delivery of Tumor-Targeted Bax-Derived Membrane-Active Peptides for the Treatment of Melanoma Tumors in a Humanized SCID Mouse Model.Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma.Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH3 mimetics - recent successes, current challenges and future promise.Synergistic killing of human small cell lung cancer cells by the Bcl-2-inositol 1,4,5-trisphosphate receptor disruptor BIRD-2 and the BH3-mimetic ABT-263.The Complex Link between Apoptosis and Autophagy: a Promising New Role for RB.Small-cell lung cancer: what we know, what we need to know and the path forward.Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase-targeted therapy in lung and gastric cancer.ABT-263 induces G1/G0-phase arrest, apoptosis and autophagy in human esophageal cancer cells in vitro.Small molecule inhibitor TW-37 is tolerable and synergistic with chemotherapy in nasopharyngeal carcinoma.Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity.BCL-2 as therapeutic target for hematological malignancies.Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin.KPNB1 inhibition disrupts proteostasis and triggers unfolded protein response-mediated apoptosis in glioblastoma cells.The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII.
P2860
Q33608593-F11FA7BC-9BAD-44F0-8EB5-C3B1FBE0B151Q33785102-E5BE58EC-8FA7-4A12-992D-B3A4091DB34AQ34045737-7930C5FD-5111-436B-BC40-12BA4A919230Q36035933-E88D99D9-58F4-4936-9363-85F04E234A5DQ37204781-877F5139-F320-4C82-AFBF-EEFDEC74F890Q37520553-7FC24193-7C10-41DD-82C8-FE1DBF68F63BQ37587294-A2869962-D508-40EB-ABC8-42DC9356C1A0Q38599086-DE981682-D938-4118-801E-C6F3875BC27DQ38718291-2B55490D-913B-41D8-AF73-4EBEE7110D7DQ38720813-C20004B6-6632-463C-B84C-E92D9CE6F53AQ38782374-0C07DC89-2CEA-4108-BD24-8736E4DE5F72Q38807526-E1B42F2B-9A05-4AF9-ACED-A669126D88F1Q39043141-2495EFE1-FA3D-4051-932C-BC21EF44E765Q47595394-FAA14FAC-1364-4797-9BD6-B3C9C47E326CQ47835496-0D867400-78A8-4A03-8FD5-F884E3AA32CEQ50887989-5EC9839E-16DC-4F95-A673-757AE21CC7F2Q50897221-55D2B922-0F58-45ED-9E31-645DE5B5CD20Q52538370-768D3A78-B5B8-480E-95CC-2BDDF4D6C46DQ53684488-C9626CA7-FA74-47A9-AF9D-CA5AFEF1084EQ55073638-63F1B2DD-751F-4BF8-A7D2-943386BB75EDQ55081473-C2C56D87-C134-435C-A1D5-76D8138F4654Q55422121-B0C59E17-B8AB-4BCA-BE32-9C42C0786EDE
P2860
Targeting BCL2-Proteins for the Treatment of Solid Tumours
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Targeting BCL2-Proteins for the Treatment of Solid Tumours
@ast
Targeting BCL2-Proteins for the Treatment of Solid Tumours
@en
Targeting BCL2-Proteins for the Treatment of Solid Tumours
@nl
type
label
Targeting BCL2-Proteins for the Treatment of Solid Tumours
@ast
Targeting BCL2-Proteins for the Treatment of Solid Tumours
@en
Targeting BCL2-Proteins for the Treatment of Solid Tumours
@nl
prefLabel
Targeting BCL2-Proteins for the Treatment of Solid Tumours
@ast
Targeting BCL2-Proteins for the Treatment of Solid Tumours
@en
Targeting BCL2-Proteins for the Treatment of Solid Tumours
@nl
P2860
P3181
P356
P1433
P1476
Targeting BCL2-Proteins for the Treatment of Solid Tumours
@en
P2093
Meike Vogler
P2860
P304
P3181
P356
10.1155/2014/943648
P407
P50
P577
2014-01-01T00:00:00Z